MaxCyte, Inc., a cell-engineering focused company of next-generation cell therapeutics, and Oribiotech Ltd.(Ori), an advanced cell and gene therapy (CGT) manufacturing technology company, entered a strategic collaboration aimed at enhancing efficiency, scalability, and productivity in cell therapy manufacturing.

This collaboration combines the MaxCyte ExPERT platform and proven Flow Electroporation technology, with Ori’s innovative next-generation cell therapy manufacturing platform, IRO (ee-RO). 

MaxCyte’s technology offers flexibility and efficiency in transfecting cells at a clinical scale, integrating with diverse upstream and downstream processes within cell therapy workflows. The IRO platform introduces automated fluid handling, customizable mixing, and the OriConnect tubeless sterile connection system, enhancing cell culture efficiency and scalability.

The collaboration will evaluate how the IRO platform can optimize the yield and streamline the manufacturing timelines of MaxCyte-engineered primary T cells compared to traditional post-electroporation cell expansion processes. Ori and MaxCyte have selected CD19 CAR expression via CRISPR knock-in in activated T cells as the test system for initial evaluation.

Jason C. Foster, CEO of Ori Biotech, said, “By integrating modular, best-of-breed technologies, we’re raising the standard of manufacturing by enhancing commercial viability. Ultimately, this collaboration helps bring cell therapies to patients faster, more reliably, and at greater scale.”

Maher Masoud, President and CEO of MaxCyte, commented, “This partnership underscores our commitment to enabling therapy developers to more effectively address the evolving demands of cell therapy manufacturing, ultimately accelerating the availability of transformative treatments for patients.”